Background: Posttraumatic stress disorder (PTSD) is a highly prevalent and
often chronic disorder among combat veterans, persisting in as many as 15%
of Vietnam veterans for at least 20 years, Treatment response in veterans w
ith combat-related PTSD has been disappointing. Although anxiolytics, antic
onvulsants, antipsychotics, and antidepressants have been tried, none has b
een consistently associated with improvement in all primary symptom domains
(i.e., intrusive recollections, avoidance/numbing, and hyperarousal). This
open-label study evaluated the use of nefazodone in a group of Vietnam vet
erans with chronic, treatment-refractory symptoms of PTSD.
Method: Male outpatients with DSM-IV PTSD who had failed a minimum of 3 pre
vious medication trials were eligible for the study. Nineteen Vietnam comba
t veterans entered the study and were treated with nefazodone, 100-600 mg/d
ay, for 12 weeks. PTSD symptoms, anxiety, depression, sleep, sexual functio
ning, and adverse events were assessed weekly.
Results: Severity of depression lessened, as did PTSD symptoms of intrusive
recollections, avoidance, and hyperarousal. Depressive symptom severity as
measured by the Beck Depression Inventory decreased by a mean of 30%. Simi
larly, there was an overall drop in the intensity of PTSD symptoms as measu
red by the Clinician Administered PTSD Scale of 32% with a 26% improvement
for symptoms of intrusion, 33% for avoidance, and 28% for arousal. In addit
ion, improvements in sleep and sexual functioning were reported. The mean d
aily dose of nefazodone after 12 weeks was 430 mg (range, 200-600 mg/day).
The most frequently reported side effects were headaches (53%), dry mouth (
42%), and diarrhea (42%), but side effects tended to be mild and transient.
Conclusion: In this group of Vietnam veterans with chronic treatment-refrac
tory PTSD and multiple comorbid Axis I psychiatric disorders, nefazodone wa
s well tolerated and effective. Larger, controlled studies are warranted.